Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 5/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765874 | 0.86 | NTRK1 (0.41) | NTRK1F2IDENAMPTPRSS1 | |
| SCHEMBL30765852 | 0.85 | NTRK1 (0.38) | NTRK1F2NAMPTMEN1KMT2A | |
| SCHEMBL30765715 | 0.85 | ATM (0.40) | SMN1; SMN2KDM4CMEN1KMT2A | |
| SCHEMBL30765915 | 0.82 | SMN1; SMN2 (0.39) | F2SMN1; SMN2NAMPTPRSS1KDM6B | |
| SCHEMBL30765520 | 0.79 | NTRK1 (0.41) | NTRK1F2NAMPTPRSS1 | |
| SCHEMBL30765718 | 0.72 | NTRK1 (0.45) | NTRK1F2IDEPRSS1MEN1 | |
| SCHEMBL30765816 | 0.72 | NTRK1 (0.38) | NTRK1SMN1; SMN2NAMPTMEN1KMT2A | |
| SCHEMBL30765854 | 0.71 | NTRK1 (0.36) | NTRK1F2NAMPTPRSS1KMT2A | |
| SCHEMBL30765582 | 0.70 | KDM4C (0.42) | NTRK1KDM4C | |
| SCHEMBL30765506 | 0.70 | NTRK1 (0.51) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |